Breaking News

AGC Biologics Expands pDNA and mRNA Manufacturing Capacity

Expansion at Heidelberg site allows the CDMO to meet increasing demands of the cell and gene therapy market.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

AGC Biologics, a global biopharmaceutical contract development and manufacturing organization (CDMO), unveiled expansion plans for the company’s Heidelberg facility to increase manufacturing capacities for plasmid-DNA (pDNA) and messenger RNA (mRNA) projects.   With this expansion, AGC Biologics is boosting its current 100L and 1,000L manufacturing capacities for a variety of different biologics projects by adding an additional GMP manufacturing line. The expansion includes a new GMP cleanroom f...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters